Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study investigated transcription factors in human trophectoderm cells during development, finding that GATA2 and GATA3 are essential for transforming stem cells into induced trophoblast stem cells, which display characteristics similar to placental progenitor cells, offering new methods for modeling placental-associated diseases.

This retrospective study evaluated the use of tofacitinib as an induction therapy for severe alopecia areata and found it promising and comparable to the standard oral mini-pulse treatment, though pulse steroids may be considered if tofacitinib response is inadequate.

Topical tofacitinib helped a man with severe scalp condition after other treatments failed.

This study found that stabilized beta-catenin is crucial for activating stem cell transition from quiescence to proliferation in hair follicles by influencing gene expression within the stem cell niche.

This case study reports significant improvements in joint pain and hair regrowth in a 31-year-old female with alopecia universalis, psoriasis vulgaris, and psoriatic arthritis using a combination of tofacitinib and methotrexate after other treatments failed.

This review concluded that oral tofacitinib and adalimumab are promising treatments for cicatricial alopecia, showing effectiveness in improving signs and symptoms but requiring regular monitoring for adverse effects. The authors emphasize the need for further extensive studies to solidify these findings.

Tofacitinib, an arthritis drug, helped hair growth in alopecia universalis but long-term safety needs more research.

This study observed that the degradation product PTeCA significantly increased in hair treated with oxidative cosmetics, suggesting it could be a reliable marker for detecting such treatments, with a proposed PTCA cut-off value using PTeCA as the gold standard.

This study found that oral tofacitinib was effective in promoting hair regrowth in patients with alopecia universalis, although further controlled studies are recommended to confirm its safety and efficacy.

In this study, tofacitinib monotherapy was effective in achieving hair regrowth in over half of Korean patients with moderate-to-severe and refractory alopecia areata, though treatment discontinuation typically led to hair loss recurrence.

This case report found that oral tofacitinib treatment resulted in more than 90% hair regrowth in a 6-year-old with severe alopecia areata, with no relapse after dose reduction.

In this study on patchy alopecia areata treatment involving 20 patients, TCA (triamcinolone acetonide) injections showed a significantly better response and minimal side effects compared to superficial cryotherapy.

Enhancing Tregs can protect against alopecia areata.

This study observed that insurance coverage for oral tofacitinib in alopecia areata patients was difficult to obtain, with 71% of patients ultimately not receiving approval despite the drug's efficacy as an off-label treatment.

This report describes an 8-year-old male with trichotillomania, confirmed by trichoscopy showing characteristic hair damage and patterns.

In this study, 65% TCA showed better improvement for acne scars compared to 50% GA, but GA may be a safer alternative with fewer adverse effects.

This study reports significant hair regrowth in 11 patients with severe alopecia areata following longstanding treatment with oral tofacitinib and also highlights successful treatment using topical tofacitinib cream in one case.

This study assessed oral tofacitinib's effectiveness and safety in treating different forms of alopecia, finding that 80% of patients experienced hair regrowth improvements over 24 weeks with no adverse events reported.

This retrospective cohort study reported that oral tofacitinib was effective in treating alopecia areata, with 83.2% of patients showing improvement and 16.0% achieving complete remission. Earlier intervention and previous hair regrowth were linked to better outcomes, and no severe adverse events were observed.

In this case report, a 42-year-old woman with cutaneous dermatomyositis showed significant improvement, including reduction of erythema, pruritus, and scaling, after starting JAK inhibitor tofacitinib, especially when conventional systemic treatments failed and intravenous immune globulin wasn't viable.

This study found that taurine and apocynin together created a synergistic effect by significantly reducing burn area damage and enhancing tissue recovery in the burn zone of stasis in rats by day 21.

This study highlights that alopecia areata, an autoimmune condition often starting in childhood, poses a higher risk of becoming chronic with an early onset and can result in poor therapy response.

This study found that high doses of TCB caused severe toxicity in cotton top marmoset monkeys, with clinical and histological changes similar to those in humans and other primates exposed to PCBs.

Tavaborole is a safe and effective toenail fungus treatment, with the 5% solution being the best option.

This study found that tofacitinib may be effective in treating various pediatric rheumatic diseases, particularly juvenile idiopathic arthritis, although some patients did not respond, and side effects were observed.

In this clinical trial, Tofacitinib effectively promoted hair regrowth in patients with alopecia areata, alopecia totalis, and alopecia universalis, with 75.6% experiencing no side effects, making it a promising treatment option according to the study.

Tofacitinib helped a teenager with severe hair loss grow hair back, but more research is needed.

This study found that high TSPEAR expression in colorectal cancer was associated with poor prognosis and correlated with various tumor and immune-related factors.

This study suggests that combining GliSODin(®) Skin Nutrients with tazarotene cream significantly benefits facial fine wrinkles, photodamage, moisture, and elasticity compared to tazarotene alone.

Tofacitinib might be used to treat hair loss.